对阿尔茨海默病的最佳干预的轻度认知障碍窗口
Kevin Mekulu1, Faisal Aqlan2, Hui Yang1
1Complex Systems Monitoring, Modeling and Control Laboratory, Pennsylvania State University, University Park, PA, USA.
Journal of Alzheimer's disease reports
|August 22, 2025
概括
早期发现阿尔茨海默病对于新疗法至关重要. 目前在初级保健和专科机构的诊断缺口延迟了轻度认知障碍 (MCI) 患者的鉴定,错过了最佳干预窗口.
科学领域:
- 神经学
- 公共卫生
- 翻译医学
背景情况:
- 美国食品和药物管理局批准的阿尔茨海默病修饰疗法需要早期诊断.
- 轻度认知障碍 (MCI) 是治疗阿尔茨海默症最有效的阶段.
- 当前的诊断实践通常在认知能力显著下降后发现AD.
研究的目的:
- 在MCI阶段早期发现阿尔茨海默病的关键差距.
- 分析阿尔茨海默病延迟诊断的后果.
- 提出将早期检测与治疗机会相结合的战略.
主要方法:
- 通过NSF I-Corps计划进行的180多个利益相关者采访的分析.
- 在初级保健,专科和诊断工具中对检测挑战的定性评估.
- 审查当前的诊断途径及其局限性.
主要成果:
- 在初级保健机构中,对于识别MCI存在显著的检测缺口.
- 专业护理的障碍阻碍了阿尔茨海默病的及时诊断.
- 现有的诊断工具不足以进行广泛的早期检测.
- 延迟诊断导致错失有效干预的机会.
结论:
- 轻度认知障碍 (MCI) 是阿尔茨海默病干预的关键窗口.
- 需要转化策略来弥合早期发现和治疗机会之间的差距.
- 改善阿尔茨海默病的早期诊断对于最大限度地提高新疗法的效益至关重要.
更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.7K
06:58Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
7.4K
相关概念视频
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
206
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
206
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Cognitive Development During Adulthood
267
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
267
Dementia
165
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
165
